Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 7/20 | 0.42 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 5/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LIPC | P11150 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19629511 | 0.90 | DYRK1A (0.39) | DYRK1AGSK3BNFATC1FEN1QPCT | |
| SCHEMBL19629553 | 0.90 | DYRK1A (0.38) | DYRK1AGSK3BQPCTIDO1 | |
| SCHEMBL19629554 | 0.89 | PDK1 (0.37) | DYRK1AGSK3BKCNH2 | |
| SCHEMBL19626271 | 0.87 | DYRK1A (0.50) | DYRK1AGSK3BNFATC1FEN1QPCT | |
| SCHEMBL20193217 | 0.86 | DYRK1A (0.40) | DYRK1AGSK3BNFATC1FEN1CHUK | |
| SCHEMBL19629510 | 0.86 | CHUK (0.36) | DYRK1AGSK3BFEN1QPCTCHUK | |
| SCHEMBL19629559 | 0.84 | PDE4B (0.41) | DYRK1AGSK3BNFATC1 | |
| SCHEMBL19629489 | 0.83 | CHUK (0.36) | DYRK1AGSK3BQPCTCHUK | |
| SCHEMBL19629491 | 0.81 | CHUK (0.47) | DYRK1AGSK3BNFATC1FEN1CHUK | |
| SCHEMBL20193214 | 0.81 | CHUK (0.41) | DYRK1AGSK3BNFATC1FEN1CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981962-B2 | Pyrazole derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K21 | DYRK1A 1349/4885GSK3B 476/4885NFATC1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.